<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Jain A</submitter><funding>NIAID NIH HHS</funding><funding>NCI NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>eadq8331</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12832182</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>387(6741)</volume><pubmed_abstract>Breakdown of every transmembrane protein trafficked to lysosomes requires proteolysis of their hydrophobic helical transmembrane domains. Combining lysosomal proteomics with functional genomic datasets, we identified lysosomal leucine aminopeptidase (LyLAP; formerly phospholipase B domain-containing 1) as the hydrolase most tightly associated with elevated endocytosis. Untargeted metabolomics and biochemical reconstitution demonstrated that LyLAP is a processive monoaminopeptidase with preference for amino-terminal leucine. This activity was necessary and sufficient for the breakdown of hydrophobic transmembrane domains. LyLAP was up-regulated in pancreatic ductal adenocarcinoma (PDA), which relies on macropinocytosis for nutrient uptake. In PDA cells, LyLAP ablation led to the buildup of </pubmed_abstract><journal>Science (New York, N.Y.)</journal><pubmed_title>Leucine aminopeptidase LyLAP enables lysosomal degradation of membrane proteins.</pubmed_title><pmcid>PMC12832182</pmcid><funding_grant_id>R35 GM149302</funding_grant_id><funding_grant_id>R01 GM112948</funding_grant_id><funding_grant_id>U54 AI170792</funding_grant_id><funding_grant_id>R01 CA260249</funding_grant_id><pubmed_authors>Olzmann JA</pubmed_authors><pubmed_authors>Gupta S</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Detomasi TC</pubmed_authors><pubmed_authors>von Linde T</pubmed_authors><pubmed_authors>Perera RM</pubmed_authors><pubmed_authors>Dawson DW</pubmed_authors><pubmed_authors>Zoncu R</pubmed_authors><pubmed_authors>Craik CS</pubmed_authors><pubmed_authors>Bommer G</pubmed_authors><pubmed_authors>Spacci M</pubmed_authors><pubmed_authors>Jain A</pubmed_authors><pubmed_authors>Rohweder P</pubmed_authors><pubmed_authors>Luo J</pubmed_authors><pubmed_authors>Citron YR</pubmed_authors><pubmed_authors>Lange M</pubmed_authors><pubmed_authors>Anderson D</pubmed_authors><pubmed_authors>Rademaker G</pubmed_authors><pubmed_authors>Heremans I</pubmed_authors><pubmed_authors>Hernandez GA</pubmed_authors></additional><is_claimable>false</is_claimable><name>Leucine aminopeptidase LyLAP enables lysosomal degradation of membrane proteins.</name><description>Breakdown of every transmembrane protein trafficked to lysosomes requires proteolysis of their hydrophobic helical transmembrane domains. Combining lysosomal proteomics with functional genomic datasets, we identified lysosomal leucine aminopeptidase (LyLAP; formerly phospholipase B domain-containing 1) as the hydrolase most tightly associated with elevated endocytosis. Untargeted metabolomics and biochemical reconstitution demonstrated that LyLAP is a processive monoaminopeptidase with preference for amino-terminal leucine. This activity was necessary and sufficient for the breakdown of hydrophobic transmembrane domains. LyLAP was up-regulated in pancreatic ductal adenocarcinoma (PDA), which relies on macropinocytosis for nutrient uptake. In PDA cells, LyLAP ablation led to the buildup of </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2026-07-15T06:07:37.72Z</modification><creation>2026-07-01T03:07:43.812Z</creation></dates><accession>S-EPMC12832182</accession><cross_references><pubmed>40146846</pubmed><doi>10.1126/science.adq8331</doi></cross_references></HashMap>